Paul Hudson, Getty Images (Bloomberg)
Sanofi hits the brakes on a top pivotal program following 'new adverse events'
According to a trio of hemophilia patient groups, Sanofi has hit the brakes on a slate of late-stage studies for fitusiran, one of their Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
